Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07419347

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
AbbVie · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Conditions

Timeline

Start date
2026-02-27
Primary completion
2026-06-01
Completion
2026-06-01
First posted
2026-02-19
Last updated
2026-04-16

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT07419347. Inclusion in this directory is not an endorsement.

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data (NCT07419347) · Clinical Trials Directory